Céline Desvignes

Céline Desvignes

Auto-generated profile, based on publicly available information

Céline Desvignes

CHRU de Tours, Plateforme Recherche Centre Pilote de suivi Biologique des traitements par Anticorps (CePiBAc) Tours France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
CBClaire Bonneau
Claire Bonneau
GPGilles Paintaud
Gilles Paintaud
OTOlivier Trédan
Olivier Trédan
CDCoraline Dubot
Coraline Dubot
CDCéline Desvignes
Céline Desvignes
MGMaya Gutierrez
Maya Gutierrez

23 August 2023 in Journal of Internal Medicine
Verified
Journal Article
Open access
SDSophie Dupuis-Girod
Sophie Dupuis-Girod
SRSophie Rivière
Sophie Rivière
CLChristian Lavigne
Christian Lavigne
AFAnne‐Emmanuelle Fargeton
Anne‐Emmanuelle Fargeton
BGBrigitte Gilbert‐Dussardier
Brigitte Gilbert‐Dussardier
TCThierry CHINET
Thierry CHINET
Background: Bevacizumab—a humanized monoclonal antibody—has been widely used to treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has yet been conducted.Methods: This study is a double‐blind multicenter randomized phase 2 trial with a 1:1 active‐treatment‐to‐placebo ratio. We included patients over the age of 18 with a confirmed diagnosis and the need for at least four red blood cell (RBC) units transfused in the 3 months before study enrollment. Bevacizumab was administered at a dose of 5 mg/kg every 14 days with a total of six injections. The primary efficacy criterion was a decrease of at least 50% in the cumulative number of RBC units transfused in a 3‐month period before and after treatment.Results: A total of 24 patients (12 in each group) were included and randomized at 4 different centers. In intention‐to‐treat analysis, 63.6% of patients (7/11) in the bevacizumab group versus 33.3% of patients (4/12) in the placebo group decreased the number of blood transfusions by at least 50% (p = 0.22). Hemoglobin levels significantly improved at 6 months in the bevacizumab versus placebo group (p = 0.02). The pharmacokinetics study revealed that patients with high exposure to bevacizumab had a significant decrease in RBC transfusions (p = 0.03). Fifty‐nine adverse events were observed, 34 in the placebo arm versus 25 in the bevacizumab arm.Conclusion: Though the present trial was underpowered, patients with HHT receiving bevacizumab required numerically fewer red blood cell transfusions than those receiving placebo, particularly those with high exposure.

13 November 2021 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
ABAmina Bensalem
Amina Bensalem
GCGuillaume Cartron
Guillaume Cartron
USUlrich Specks
Ulrich Specks
DMDenis Mulleman
Denis Mulleman
EGEmmanuel Gyan
Emmanuel Gyan
DTDavid Ternant
David Ternant

1 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DTDavid Ternant
David Ternant
OTOlivier Le Tilly
Olivier Le Tilly
LPLaurence Picon
Laurence Picon
DMDriffa Moussata
Driffa Moussata
CPChristophe Passot
Christophe Passot
GPGilles Paintaud
Gilles Paintaud
Infliximab is an anti-TNF-α monoclonal antibody approved in chronic inflammatory bowel diseases (IBD). This study aimed at providing an in-depth description of infliximab target-mediated pharmacokinetics in 133 IBD patients treated with 5 mg/kg infliximab at weeks 0, 2, 14, and 22. A two-compartment model with double target-mediated drug disposition (TMDD) in both central and peripheral compartments was developed, using a rich database of 26 ankylosing spondylitis patients as a reference for linear elimination kinetics. Population approach and quasi-steady-state (QSS) approximation were used. Concentration-time data were satisfactorily described using the double-TMDD model. Target-mediated parameters of central and peripheral compartments were respectively baseline TNF concentrations (RC0 = 3.3 nM and RP0 = 0.46 nM), steady-stated dissociation rates (KCSS = 15.4 nM and KPSS = 0.49 nM), and first-order elimination rates of complexes (kCint = 0.17 day−1 and kPint = 0.0079 day−1). This model showed slower turnover of targets and infliximab-TNF complex elimination rate in peripheral compartment than in central compartment. This study allowed a better understanding of the multi-scale target-mediated pharmacokinetics of infliximab. This model could be useful to improve model-based therapeutic drug monitoring of infliximab in IBD patients.

25 June 2021 in Biomarkers in Medicine
Verified
Journal Article
Closed access
RCRomain Chautard
Romain Chautard
LCLaetitia Corset
Laetitia Corset
SISajida Ibrahim
Sajida Ibrahim
CDCéline Desvignes
Céline Desvignes
GPGilles PAINTAUD
Gilles PAINTAUD
WRWilliam Raoul
William Raoul
Background & aim: Resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (CRC) is frequent and prognostic biomarkers are lacking. MicroRNAs (miR) are good candidates in this ...

18 January 2018 in Bioanalysis
Verified
Journal Article
Closed access
CDCéline Desvignes
Céline Desvignes
CPChristophe Passot
Christophe Passot
DTDavid Ternant
David Ternant
MCMorgane Caulet
Morgane Caulet
CGCaroline Guérineau
Caroline Guérineau
GPGilles Paintaud
Gilles Paintaud
Aim: Panitumumab is a monoclonal antibody directed against EGFR that is approved for the treatment of metastatic colorectal cancer. To investigate its pharmacokinetics and concentration–response relationship, a validated assay is required. Results: An ELISA assay was developed and validated according to international recommendations. Six calibrators (ranging from 0.1 to 20 mg/l) plus one anchor point (50 mg/l) and three quality controls (0.45, 2 and 8 mg/l) were defined. The limit of detection, lower limit of quantification and upper limit of quantification were 0.033, 0.112 and 10 mg/l, respectively. Conclusion: This method is validated and can be used to study pharmacokinetics of panitumumab or to perform therapeutic drug monitoring.